Literature DB >> 6166555

Artificial Salmonella vaccines: Salmonella typhimurium O-antigen-specific oligosaccharide-protein conjugates elicit protective antibodies in rabbits and mice.

S B Svenson, A A Lindberg.   

Abstract

Several saccharides representative of the O-antigenic polysaccharide chain of Salmonella typhimurium (O antigens 4 and 12) were used as haptenic groups covalently linked to bovine serum albumin. The disaccharide abequose 1 --> 3 D-mannose was synthesized, and the [Formula: see text] tetra-, octa- and dodecasaccharides were isolated after cleavage of isolated S. typhimurium O-polysaccharide chains by using bacteriophage endo-glycosidases. Rabbits immunized with the saccharide-protein conjugates suspended in Freund complete adjuvant readily responded with O4 antibody titers as high, or almost as high, as those elicited by heat-killed bacteria. The octa- and dodecasaccharide conjugates also gave rise to O12 antibody titers. The antibody response in mice differed in two ways from that seen in rabbits: mice did not respond with measurable antibody production against the disaccharide haptens, and the highest S. typhimurium lipopolysaccharide antibody response elicited by the saccharide haptens was still approximately 50-fold lower than that elicited by heat-killed bacteria. The latter difference may be a consequence of the fact that the mouse preferentially produces antibodies against the galactose residue which is terminal in the hapten but not in the native O-antigenic polysaccharide chain. Antibodies elicited in rabbits against all saccharide-protein conjugates protected passively transferred mice against intraperitoneal challenge with 100 times the 50% lethal dose of S. typhimurium SH 2201 (O4, 12) but not against challenge with S. enteritidis SH 2204 (O9, 12). The antibodies elicited by the saccharide-protein conjugates protected as well as antibodies elicited by heat-killed bacteria.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6166555      PMCID: PMC351472          DOI: 10.1128/iai.32.2.490-496.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  Susceptibility of CBA/N mice to infection with Salmonella typhimurium: influence of the X-linked gene controlling B lymphocyte function.

Authors:  A D O'Brien; I Scher; G H Campbell; R P MacDermott; S B Formal
Journal:  J Immunol       Date:  1979-08       Impact factor: 5.422

2.  Immunochemistry of Salmonella O-antigens: specificity of rabbit antibodies against the O-antigen 4 determinant elicited by whole bacteria and O-antigen 4 specific saccharide-protein conjugates.

Authors:  H J Jörbeck; S B Svenson; A A Lindberg
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

3.  Evidence for O antigens as the antigenic determinants in "ribosomal" vaccines prepared from Salmonella.

Authors:  T K Eisenstein
Journal:  Infect Immun       Date:  1975-08       Impact factor: 3.441

4.  Enzyme-linked immunosorbent assay (ELISA) for titration of antibodies against Brucella abortus and Yersinia enterocolitica.

Authors:  H E Carlsson; B Hurvell; A A Lindberg
Journal:  Acta Pathol Microbiol Scand C       Date:  1976-06

5.  Immunochemistry of Salmonella O-antigens: preparation of an octasaccharide-bovine serum albumin immunogen representative of Salmonella serogroup B O-antigen and characterization of the antibody response.

Authors:  S B Svenson; A A Lindberg
Journal:  J Immunol       Date:  1978-05       Impact factor: 5.422

6.  Comparative efficacy and toxicity of a ribosomal vaccine, acetone-killed cells, lipopolysaccharide, and a live cell vaccine prepared from Salmonella typhhimurium.

Authors:  C R Angerman; T K Eisenstein
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

7.  Protective effects of a supernatant factor from Salmonella typhimurium on Salmonella typhimurium infection of inbred mice.

Authors:  J Plant; A A Glynn; B M Wilson
Journal:  Infect Immun       Date:  1978-10       Impact factor: 3.441

8.  Coupling of acid labile Salmonella specific oligosaccharides to macromolecular carriers.

Authors:  S B Svenson; A A Lindberg
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

9.  Distinct functions of monoclonal IgG antibody depend on antigen-site specificities.

Authors:  W Schalch; J K Wright; L S Rodkey; D G Braun
Journal:  J Exp Med       Date:  1979-04-01       Impact factor: 14.307

10.  Binding properties of immunoglobulin combining sites specific for terminal or nonterminal antigenic determinants in dextran.

Authors:  J Cisar; E A Kabat; M M Dorner; J Liao
Journal:  J Exp Med       Date:  1975-08-01       Impact factor: 14.307

View more
  39 in total

1.  Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls.

Authors:  E Konadu; J Shiloach; D A Bryla; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Anti-Salmonella lipopolysaccharide monoclonal antibodies: characterization of Salmonella BO-, CO-, DO-, and EO-specific clones and their diagnostic usefulness.

Authors:  J M Luk; A A Lindberg
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

Review 3.  Mouse models to assess the efficacy of non-typhoidal Salmonella vaccines: revisiting the role of host innate susceptibility and routes of challenge.

Authors:  Raphael Simon; Sharon M Tennant; James E Galen; Myron M Levine
Journal:  Vaccine       Date:  2011-05-25       Impact factor: 3.641

Review 4.  Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.

Authors:  Miguel O'Ryan; Roberto Vidal; Felipe del Canto; Juan Carlos Salazar; David Montero
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 5.  Antibodies and Protection in Systemic Salmonella Infections: Do We Still Have More Questions than Answers?

Authors:  Pietro Mastroeni; Omar Rossi
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.441

6.  A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection.

Authors:  Sharavathi Guddehalli Parameswarappa; Katrin Reppe; Andreas Geissner; Petra Ménová; Subramanian Govindan; Adam D J Calow; Annette Wahlbrink; Markus W Weishaupt; Bopanna Ponnappa Monnanda; Roland Lawrence Bell; Liise-Anne Pirofski; Norbert Suttorp; Leif Erik Sander; Martin Witzenrath; Claney Lebev Pereira; Chakkumkal Anish; Peter H Seeberger
Journal:  Cell Chem Biol       Date:  2016-11-03       Impact factor: 8.116

Review 7.  Glycoconjugate vaccine strategies for protection against invasive Salmonella infections.

Authors:  Raphael Simon; Myron M Levine
Journal:  Hum Vaccin Immunother       Date:  2012-02-28       Impact factor: 3.452

8.  Role of gamma interferon in late stages of murine salmonellosis.

Authors:  A Muotiala; P H Mäkelä
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

9.  Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid.

Authors:  C Y Chu; B K Liu; D Watson; S S Szu; D Bryla; J Shiloach; R Schneerson; J B Robbins
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

10.  Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine.

Authors:  D C Watson; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.